Session Information
-
WCLC 2021
2021 World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
All times listed are in Mountain Time MDT (UTC-6:00)
PL - Plenary
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
WS - Workshops
IS - Industry Symposium
MTE - Meet the Expert
BEDG - Brain Exchange Discussion Groups
September 8 Wed
Sep 8 Thursday
September 9 Thu
Sep 9 Friday
September 10 Fri
Sep 10 Saturday
September 11 Sat
Sep 11 Sunday
September 12 Sun
Sep 12 Monday
September 13 Mon
Sep 13 Tuesday
September 14 Tue
Sep 14
-
+
MA01 - Multimodality Management of Advanced Lung Cancer
- 08:15 - 09:15
- 9/08/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Multimodality of Advanced Lung Cancer
-
+
MA01.05 - Sintilimab, SBRT and GM-CSF for Advanced NSCLC: Safety Run-in Results of a Prospective, Multicenter, Phase II Trial
08:45 - 08:50 | Presenter: Jianjiao Ni
- Abstract
Loading...
-
+
MA02 - RET and Novel Combinations of Osimertinib
- 09:30 - 10:30
- 9/08/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Novel Therapeutics and Targeted Therapies
-
+
MA02.01 - Efficacy and Safety of Selpercatinib in Chinese Patients With RET Fusion-Positive Non-Small Cell Lung Cancer: A Phase 2 Trial
09:30 - 09:35 | Presenter: Shun Lu
- Abstract
Loading...
-
+
P16 - Immunotherapy (Phase II/III Trials) - First-Line, Advanced NSCLC
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P16.04 - A Phase II Clinical Study Evaluating Camrelizumab Combined With Apatinib and Albumin Paclitaxel for Advanced Non-Small CellLung Cancer
00:00 - 00:00 | Presenter: Lin Wu
- Abstract
Loading...
-
+
P17 - Immunotherapy (Phase II/III Trials) - First-Line, Advanced, Squamous NSCLC
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P17.01 - KEYNOTE-407 China Extension Final Analysis: Pembrolizumab Plus Chemotherapy for the Treatment of Metastatic Squamous NSCLC
00:00 - 00:00 | Presenter: Ying Cheng
- Abstract
Loading...
-
+
P40 - Multimodality of Advanced Lung Cancer - Clinical Outcomes
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Multimodality of Advanced Lung Cancer
-
+
P40.14 - Efficacy and Safety of Endostar Combined With Camrelizumab and Chemotherapy in Treatment of Advanced NSCLC: A Multi-Center Retrospective Study
00:00 - 00:00 | Presenter: Lin Wu
- Abstract
Loading...
-
+
P48 - Novel Therapeutics and Targeted Therapies - EGFR
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
-
+
P48.01 - Anlotinib Plus Docetaxel vs Docetaxel for 2nd-Line Treatment of EGFR negative NSCLC (ALTER-L018): A Randomized Phase II Trial
00:00 - 00:00 | Presenter: Lin Wu
- Abstract
Loading...
-
+
MA13 - Building on the Past: What Will Be the Next Immunotherapy Combination?
- 17:30 - 18:30
- 9/13/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Immunotherapy (Phase II/III Trials)
-
+
MA13.08 - CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC
18:10 - 18:15 | Presenter: Jie Wang
- Abstract
Loading...